HS
AVDL

HighVista Strategies’s Avadel Pharmaceuticals AVDL Stock Holding History

HighVista Strategies’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-93,059
Closed -$841K – 123
2021
Q1 		$841K Sell
93,059
-18,372
-16% -$149K 0.62% 26
2020
Q4 		$744K Buy
111,431
+53,936
+94% +$337K 0.48% 51
2020
Q3 		$290K Buy
57,495
+6,087
+12% +$44.3K 0.21% 69
2020
Q2 		$415K Buy
+51,408
New +$453K 0.34% 56

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

HighVista Strategies's AVDL Position: Q2 2021 in Review

HighVista Strategies sold out of Avadel Pharmaceuticals (AVDL) in Q2 2021, closing a stake of 93,059 shares — an estimated $841K sold.

HighVista Strategies first reported a position in AVDL in Q2 2020 and held it in 4 quarters. The position peaked at $841K in Q1 2021. 80 funds tracked by Wall St. Rank hold AVDL as of Q2 2021.

  • HighVista Strategies reported no remaining Avadel Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • HighVista Strategies sold 93,059 Avadel Pharmaceuticals shares in Q2 2021, an estimated $841K.
  • HighVista Strategies first reported a position in Avadel Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • HighVista Strategies's Avadel Pharmaceuticals position peaked at $841K in Q1 2021.
  • 80 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2021.

Based on HighVista Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.